Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dendreon will have to wait until mid-2009 at the earliest for final study results of its prostate cancer vaccine Provenge, after it failed to meet the primary endpoint in an interim look at the data
You may also be interested in...
The Endgame on Oncology Endpoints
The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.
Dendreon Catches A Break For Provenge
Amended FDA agreement hastens IMPACT final analysis by one year.
Dendreon’s Therapeutic Vaccine Provenge Gets “Complete Response” From FDA
FDA is requesting additional clinical data to support the efficacy of Dendreon’s BLA.